Stockreport

ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF IBRX's lead product Anktiva has achieved rapid revenue growth and multiple regulatory approvals, but adoption and near-term revenue remain modest versus my expectations [Read more]